Perelel Reaches $100 Million Annual Revenue Run Rate

The women's health brand hit the milestone in 2026 after expanding its product line beyond prenatal vitamins.

Updated on Oct. 15, 2026 in Pregnancy

Women's health brand Perelel hit a $100 million annual revenue run rate in 2026, driven by a successful expansion into protein and supplement powders. AI Illustration. Upload story photo >

Live Poll

Do you prefer buying health supplements from brands that offer a broad range of products?

In 2026, Perelel achieved a $100 million annual revenue run rate as it diversified its offerings to include supplement powders and plant-based protein. The company has raised a total of $40 million to date.

Why it matters

By expanding its product portfolio, the company successfully reached women outside of the motherhood journey. This strategy helped broaden the brand's customer base and contributed to its profitability.

Powders currently account for 15 percent of the company's total business. A clinical study conducted in August 2026 verified the metabolic and cognitive health benefits associated with the brand's triple-support protein.

The players

Perelel

This women's health company specializes in supplements and protein products developed alongside medical professionals.

Prelude Growth Partners

This investment firm provides capital to consumer brands and contributed $27 million to Perelel in 2025.

The details

Perelel uses customer feedback, clinical research, and OB-GYN recommendations to develop its products. Half of the customers purchasing the protein line were previously new to the brand, indicating successful acquisition strategies.

September 2020: Perelel launched with five vitamin packs.
2025: Prelude Growth Partners invested $27 million.
August 2026: Clinical study found health benefits in protein powder.
2026: Perelel reached $100 million revenue run rate.
December 2026: Perelel achieves two years of profitability.

Culture Shift

Perelel's growth aligns with the broader rise of personalized women's health and wellness consumer products. This shift reflects a move away from generic wellness toward specialized care based on clinical research.

Consumers can expect the brand to continue its focus on clinical research and OB-GYN-backed formulations as it expands its inventory. These products currently require purchasing decisions based on specific health goals like metabolic or cognitive support.

The takeaway

The company's transition to a broader health brand shows how niche companies can scale by diversifying beyond their initial product focus. Customers should look for clinical evidence when evaluating wellness supplements to ensure they match their personal health needs.